Alembic Pharmaceuticals Limited Establishes New Subsidiary in Thailand to Strengthen Global Presence

Alembic Pharmaceuticals Limited has announced the incorporation of a new wholly owned subsidiary, Alembic Pharmaceuticals (Thailand) Co., Ltd., as part of its strategy to expand its global footprint. The subsidiary has been established with an initial share capital of THB 3,000,000, with the company holding a 99.99% stake. The entity is currently in the early stage and has not yet commenced operations.

Strengthening Presence in Southeast Asia

The formation of the Thailand-based subsidiary is aimed at expanding Alembic’s pharmaceutical business and strengthening its distribution network in Southeast Asia. Establishing a local corporate presence will allow the company to better navigate regulatory frameworks, enhance market access, and support the introduction of its generic formulations and APIs in the Thai pharmaceutical market.

Part of Alembic’s Global Expansion Strategy

The move aligns with Alembic’s broader strategy to expand internationally and diversify revenue streams beyond its traditional markets. In recent years, the company has undertaken several global initiatives, including establishing subsidiaries and pursuing acquisitions in key markets to strengthen its global pharmaceutical operations.